U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07290894) titled 'Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01' on Nov. 21.
Brief Summary: MITO VULVA-1 is a prospective, single arm, multi-cohorts, phase II trial that aims to assess the activity and the safety of Lenvatinib plus Pembrolizumab in patients with vulvar cancer. 80 patients will be overall enrolled in the study.Three cohorts are planned
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Vulva Cancer
Intervention:
DRUG: Pembrolizumab
Pembrolizumab 200 mg IV infusion (30 minute) is administered at Day 1 of each 21-days cycle.Pembrolizumab will be administered up to 35 cycles.
DRUG: Lenvati...